XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Operating expenses:        
Research and development (Note 8) $ (2,474) $ 14,982 $ 10,136 $ 32,607
Selling, general and administrative 12,439 5,526 22,028 12,966
Total operating expenses 9,965 20,508 32,164 45,573
Operating loss (9,965) (20,508) (32,164) (45,573)
Other income/(expense):        
Research and development tax credit (1,934) 5,409 379 6,711
Interest income 3,402 165 6,079 180
Interest expense (740) (91) (1,033) (175)
Foreign exchange gain/(loss) 740 (2,662) 1,672 (3,585)
Total other income, net 1,468 2,821 7,097 3,131
Loss before income taxes (8,497) (17,687) (25,067) (42,442)
Income tax expense (310) (79) (483) (161)
Net loss $ (8,807) $ (17,766) $ (25,550) $ (42,603)
Profit/(loss) per share, basic (in dollars per share) $ (0.01) $ (0.04) $ (0.04) $ (0.09)
Profit/(loss) per share, diluted (in dollars per share) $ (0.01) $ (0.04) $ (0.04) $ (0.09)
Weighted-average shares outstanding, basic (in shares) 634,469,423 484,777,837 627,996,124 483,226,039
Weighted-average shares outstanding, diluted (in shares) 634,469,423 484,777,837 627,996,124 483,226,039